Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.

Jesinghaus, Moritz; Steiger, Katja; Slotta-Huspenina, Julia; Drecoll, Enken; Pfarr, Nicole; Meyer, Petra; Konukiewitz, Björn; Bettstetter, Marcus; Wieczorek, Kathrin; Ott, Katja; Feith, Markus; Langer, Rupert; Weichert, Wilko; Specht, Katja; Boxberg, Melanie

doi:10.18632/oncotarget.18606

journal article

Document type:: Journal Article
Author(s):: Jesinghaus, Moritz; Steiger, Katja; Slotta-Huspenina, Julia; Drecoll, Enken; Pfarr, Nicole; Meyer, Petra; Konukiewitz, Björn; Bettstetter, Marcus; Wieczorek, Kathrin; Ott, Katja; Feith, Markus; Langer, Rupert; Weichert, Wilko; Specht, Katja; Boxberg, Melanie
Title:: Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Abstract:: Esophageal squamous cell carcinoma (ESCC) is the most common esophageal cancer associated with poor prognosis and additional therapeutic strategies must be implemented to optimize ESCC treatment. Meanwhile, the important biologic role and potential prognostic and therapeutic implications of a tumors immunologic microenvironment (IM) have been recognized in various cancers.In order to investigate the contexture and the prognostic relevance of the IM in ESCC, we immunohistochemically evaluated the extent of overall/intraepithelial TILs (CD3+/CD8+) and of PD-1 / PD-L1 expression in a cohort of 125 therapy-naive ESCCs, additionally assessing PD-L1 copy number status via fluorescence in-situ hybridization.High intraepithelial CD3+ TILs (CD3ihigh) and high PD-L1 expression on tumor cells (PD-L1high) were each significantly associated with improved overall- (OS) (CD3+: p = 0.019; PD-L1: p = 0.028), disease specific- (DSS) (CD3+: p = 0.05; PD-L1: p = 0.006) and disease free survival (DFS) (CD3+: p = 0.009; PD-L1: p < 0.001). CD3ihigh- and PD-L1high cases were significantly associated with one another (p < 0.001). Subgrouping of ESCC revealed decreased OS (p = 0.031), DSS (p = 0.012) and DFS (p < 0.001) for CD3ilow/PD-L1low cancers.Our data not only associate CD3ihigh- and PD-L1high ESCC with a beneficial outcome, but also demonstrate PD-L1high- and CD3ihigh status to be closely intertwined. Furthermore, our study demarcates a prognostically unfavorable, "non-immunoreactive" CD3ilow / PD-L1low ESCC-subgroup, potentially forming the basis for an immune-based stratification of ESCC.
Journal title abbreviation:: Oncotarget
Year:: 2017
Journal volume:: 8
Journal issue:: 29
Pages contribution:: 46756-46768
Language:: eng
Fulltext / DOI:: doi:10.18632/oncotarget.18606
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/28657901
TUM Institution:: Chirurgische Klinik und Poliklinik; Institut für Allgemeine Pathologie und Pathologische Anatomie
BibTeX